# US 2025/0375446 A1 · Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375446 A1
- Document ID: US20250375446A1
- Status: Published application
- Kind: A1
- Application number: 19/311,292
- Filed: 2025-08-27
- Published: 2025-12-11
- Earliest claimed: 2019-05-23
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Souvik BHATTACHARYA; Bruno BIETH; Maciej CABANSKI; Bruno CENNI; Stefan DE BUCK; Martin KAUL; Arvind KINHIKAR; Andrijana RADIVOJEVIC; Thomas SEVERIN; Julian STORIM; Alessandra VITALITI GARAMI
- Web page: https://patentgrep.com/patent/US20250375446A1

## CPC

- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61P 17/00: Drugs for dermatological disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods for treating Chronic Spontaneous Urticaria using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating Chronic Spontaneous Urticaria patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, for use in the treatment of chronic spontaneous urticaria (CSU) in a subject in need of such treatment, wherein the daily dose of compound of Formula (I) is from about 10 mg to about 200 mg.

### Claim 2 (depends on 1)

The compound of Formula (I) or a pharmaceutically acceptable salt thereof, for use according to claim 1, wherein the daily dose is from about 10 mg to about 100 mg.

### Claim 3 (depends on 1)

The compound of Formula (I) or a pharmaceutically acceptable salt thereof, for use according to claim 1, wherein the daily dose is about 100 mg.

### Claim 4 (depends on 1)

The compound of Formula (I) or a pharmaceutically acceptable salt thereof, for use according to claim 1, wherein the daily dose is about 50 mg.

### Claim 5 (depends on 1)

The compound of Formula (I) or a pharmaceutically acceptable salt thereof, for use according to claim 1, wherein the daily dose is about 35 mg.

### Claim 6 (depends on 1)

The compound of Formula (I) or a pharmaceutically acceptable salt thereof, for use according to claim 1, wherein the daily dose is about 25 mg.

### Claim 7 (depends on 1)

The compound of Formula (I) or a pharmaceutically acceptable salt thereof, for use according to claim 1, wherein the daily dose is about 20 mg.

### Claim 8 (depends on 1)

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use according to claim 1, wherein the compound of Formula (I) is administered once a day in a dose of about 10 mg, about 35 mg, about 50 mg or about 100 mg.

### Claim 9 (depends on 1)

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use according to claim 1, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in a dose of about 10 mg, about 25 mg, about 50 mg or about 100 mg twice daily.

### Claim 10

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use according to any of the preceding claims, wherein, prior to treatment with the compound of Formula (I), the subject has been previously treated with a systemic agent for CSU.

### Claim 11 (depends on 10)

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use according to claim 10, wherein the systemic agent is selected from the group consisting of H1-antihistamines (H1-AH), H2-antihistamines (H2-AH), and a leukotriene receptor antagonist (LTRA) and combinations thereof.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use according to any of claims 1-9, wherein, prior to treatment with the compound of Formula (I), the subject has not been previously treated with a systemic agent for CSU.

### Claim 13

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use according to any of the preceding claims, wherein the subject has moderate to severe CSU.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use according to any of claims 1-12, wherein the subject is selected according to at least one of the following criteria:
a) prior to treatment with compound of Formula (I) or a pharmaceutically acceptable salt thereof, the subject has an UAS7 score of≥16;
b) prior to treatment with the compound of Formula (I) or a pharmaceutically acceptable salt thereof, the subject has an HSS7 score≥8.

### Claim 15

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use according to any of the preceding claims, wherein the subject is an adult.

### Claim 16

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use according to any one of the preceding claims, wherein said subject achieves by week 4 or at week 12 of treatment at least one of the following:
a) a reduction of hives and itch as measured by a UAS≤6; or a complete absence of hives and itch (UAS7=0); or
b) a Dermatology Life Quality Index (DLQI)=0−1;
c) an absence of Angiodema as measured by the angiodema activity score (AAS7) of zero.

### Claim 17

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use according to any of preceding claims, wherein said subject achieves a sustained response as measured by complete hives and itch response ([UAS7]=0) and/or a Dermatology Life Quality Index (DLQI)=0−1 and/or a continued absence of angiodema (AAS7=0) at week 4 after completion of the treatment.

### Claim 18

The compound of Formula (I) or a pharmaceutically acceptable salt thereof, for use according to any of the preceding claims, wherein the compound of Formula (I), or pharmaceutically acceptable salt thereof is disposed in a pharmaceutical formulation and wherein said pharmaceutical formulation further comprises pharmaceutically acceptable carriers.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use according to any of claims 1-17, wherein the compound of Formula (I); or a pharmaceutically acceptable salt thereof, has a Tmax of about 0.5-3 hours.
